Free Trial
ASX:MYX

Mayne Pharma Group (MYX) Stock Price, News & Analysis

Mayne Pharma Group logo

About Mayne Pharma Group Stock (ASX:MYX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
5.47 million shs
Average Volume
N/A
Market Capitalization
$446.85 million
P/E Ratio
N/A
Dividend Yield
0.84%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Remove Ads
Receive MYX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mayne Pharma Group and its competitors with MarketBeat's FREE daily newsletter.

MYX Stock News Headlines

Mayne Pharma Group Ltd (HG6.HM)
Trump to unlock 15-figure fortune for America (May 3rd) ?
We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public.
Insignia Financial Acquires Stake in Mayne Pharma
See More Headlines

MYX Stock Analysis - Frequently Asked Questions

Mayne Pharma Group Limited (ASX:MYX) announced its quarterly earnings data on Friday, February, 22nd. The company reported $0.02 EPS for the quarter. Mayne Pharma Group had a negative net margin of 44.86% and a negative trailing twelve-month return on equity of 34.78%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mayne Pharma Group investors own include Appen (APX), Aurora Cannabis (ACB), Sundance Energy (SNDE), Turquoise Hill Resources (TRQ), Pilbara Minerals (PILBF), Organigram (OGI) and Karoon Energy (KAR).

Company Calendar

Last Earnings
2/22/2019
Today
4/04/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
ASX:MYX
CIK
N/A
Fax
N/A
Employees
780
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
0.51
Net Income
$-168,620,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$388.40 million
Price / Cash Flow
7.20
Book Value
A$5.59 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$446.85 million
Optionable
Not Optionable
Beta
1.24
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (ASX:MYX) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners